203, Aakar Complex-1, Tithal Road, Valsad-396 001. E-mail : ca.grparekh@gmail.com

FRN No.: 131167W

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Atul Brasil Quimicos Ltda

Report on the Audit of the Special Purpose Financial Statements

1. Opinion

We have audited the accompanying Special Purpose Financial Statements of **Atul Brasil Quimicos Ltda** (the "Company"), which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows and the Statement of Changes in Equity for year then ended, and a summary of significant accounting policies and other explanatory information (the "Special Purpose Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Special Purpose Financial Statements is prepared, in all material respects, in accordance with the basis of preparation set out in Note 1 to the Special Purpose Financial Statements.

2. Basis for Opinion

We conducted our audit of the Special Purpose Financial Statements in accordance with the Standards on Auditing ("SA"s) issued by the Institute of Chartered Accountants of India ("ICAI"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Special Purpose Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the ICAI together with the ethical requirements that are relevant to our audit of the Special Purpose Financial Statements under the provisions of the Companies Act, 2013 (the "Act") and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Special Purpose Financial Statements.

3. Emphasis of Matter

Basis of preparation and restriction on distribution and use

We draw attention to Note 1 to the Special Purpose Financial Statements, which describes the purpose and basis of preparation. The Special Purpose Financial Statements have been prepared by the Company solely for the purpose of submission to Authorised Dealer Category-I bank or the Reserve Bank of India (RBI) or any other regulatory authority as required under applicable regulations in connection with Annual Performance Report (APR) filing and for inclusion in the Consolidated Financial Statements of the Parent Company. As a result, the Special Purpose Financial Statements may not be suitable for any other purpose. Our report is intended solely for the purpose of submission to Authorised Dealer Category-I bank or the Reserve Bank of India (RBI) or any other regulatory authority as required under applicable regulations, for use by the Company, the Parent Company and the auditors of the Parent Company for their consideration into the audit of Consolidated Financial Statements as mentioned above and is not to be used, referred to or distributed for any other purpose without our prior written consent.

Our opinion is not modified in respect of this matter.

4. Responsibilities of Management and Those Charged with Governance for the Special Purpose Financial Statements

The Management of the Company is responsible for the preparation and presentation of these Special Purpose Financial Statements in accordance with the basis of preparation as set out in Note 1 to the Special Purpose Financial Statements for the purpose set out in Emphasis of Matter – "Basis of preparation and restriction on distribution and use" paragraph above.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Special Purpose Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Special Purpose Financial Statements by the Board of Directors of the Company, as aforesaid.

In preparing the Special Purpose Financial Statements, the Management of the Company is responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Management is also responsible for overseeing the financial reporting process of the Company.

5. Auditor's Responsibilities for the Audit of the Special Purpose Financial Statements

Our objectives are to obtain reasonable assurance about whether the Special Purpose Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs and other pronouncements issued by ICAI will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Special Purpose Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Special Purpose Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the internal financial control of the Company.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Special Purpose Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Special Purpose Financial Statements, including the disclosures, and whether the Special Purpose Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Special Purpose Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Special Purpose Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Special Purpose Financial Statements.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Ghanshyam Parekh & Co. Chartered Accountants

(Firm's Registration No. 131167W)

Proprietor

(Membership No. 030530)

UDIN: 25030530BMODNG2326

Place: Atul

Date:8th April, 2025

Atul Brasil Quimicos Ltda Balance Sheet as at March 31, 2025

| Particulars | Note | As at | Brazilian Real (R\$ As at | |
|--|--------------------|----------------|-------------------------------------|--|
| | | March 31, 2025 | March 31, 2024 | |
| A ASSETS | | | | |
| 1. Current assets | | | | |
| a) Financial assets | | | | |
| i) Trade receivables | 2 | 4,90,386 | 82,170 | |
| ii) Cash and cash equivalents | 3 | 2,91,511 | | |
| iii) Other financial assets | 4 | 2,51,511 | 13,12,128 | |
| b) Other current assets | 5 | 21,510 | 15,12,126 | |
| Total current assets | J | 8,03,407 | | |
| Total assets | | 8,03,407 | 15,33,616 | |
| B EQUITY AND LIABILITIES | | 0,00,407 | 13,33,010 | |
| Equity | | | | |
| a) Equity share capital | 6 | 7,06,899 | 7,06,899 | |
| b) Other equity | 7 | 12,126 | , , | |
| Total equity | | 7,19,025 | | |
| Liabilities | | , 120,020 | 12,02,300 | |
| 1. Current liabilities | | | | |
| a) Financial liabilities | | | | |
| i) Trade payables | 8 | 84,382 | 271110 | |
| Total current liabilities | 0 | 84,382 | | |
| Total liabilities | | 84,382 | | |
| Total equity and liabilities | | 8,03,407 | 15,33,616 | |
| ne accompanying Notes 1-13 form an integral part of the Fi | nancial Statements | 0,00,407 | 13,33,016 | |

For Ghanshyam Parekh & Co.

Firm Registration No. 131167W

Chartered Accountants

G R Parekh

Proprietor

Membership No. F-030530

T.R Gopi Kannan

President - Finance

General Manager Finance - CP Division

Atul April 08, 2025



Atul Brasil Quimicos Ltda Statement of Profit and Loss

for the year ended on March 31, 2025

| Brazilian Real (R | | | zilian Real (R\$) |
|--|------|-----------|-------------------|
| Particulars | Note | 2024-25 | 2023-24 |
| INCOME | | | |
| Revenue from operations | 9 | 5,06,065 | 5,28,733 |
| Other income | 10 | 5,49,226 | (50,122) |
| Total income | | 10,55,291 | 4,78,611 |
| EXPENSES | | | |
| Employee benefit expense | 11 | 5,12,694 | 4,93,000 |
| Other expenses | 12 | 2,74,844 | 4,26,704 |
| Total expenses | | 7,87,538 | 9,19,704 |
| Profit before tax | | 2,67,753 | (4,41,093) |
| Tax expense | | - | - |
| Total tax expense | | - | - |
| Profit for the year Other comprehensive income | | 2,67,753 | (4,41,093) |
| | | - | - |
| Total comprehensive income for the year | | 2,67,753 | (4,41,093) |
| Earning per equity share of R\$ 1 each | | | |
| Basic earning R\$ | | 0.38 | (0.62) |
| Diluted earning R\$ | | 0.38 | (0.62) |

The accompanying Notes 1-13 form an integral part of the Financial Statements.

For Ghanshyam Parekh & Co.

Firm Registration No. 131167W

Chartered Accountants

G R Parekh

Esparell

Proprietor

Membership No. F-030530

No. 30530

TR Gopi Kannan

President - Finance

Vishal Adesara

General Manager Finance - CP Division

Atul April 08, 2025

Atul Brasil Quimicos Ltda Statement of Cash Flows

for the year ended on March 31, 2025

| | | | В | razilian Real (R\$) |
|--------|---|-----|------------|---------------------|
| | Particulars | | 2024-25 | 2023-24 |
| A. | CASH FLOW FROM OPERATING ACTIVITIES | | | |
| | Profit (loss) before tax | | 2,67,753 | (4,41,093) |
| | Adjustments for: | | | |
| | Interest received | | 6,427 | _ |
| | Operating profit (loss) before change in operating assets and liabilities | | 2,61,326 | (4,41,093) |
| •••••• | Adjustments for: | | | |
| | Trade receivables | | (4,08,217) | (82,145) |
| | Other current assets | | 13,08,528 | 3,47,786 |
| | Trade payables | | (1,86,728) | 45,571 |
| | Other current financial liabilities | | - | (21,113) |
| | | | 7,13,583 | 2,90,099 |
| | Cash generated from (used in) operations | | 9,74,909 | (1,50,993) |
| | Net cash flow from (used in) operating activities | Α | 9,74,909 | (1,50,993) |
| В. | CASH FLOW FROM INVESTING ACTIVITIES | | | |
| | Dividend on equity shares | | (8,11,234) | _ |
| | Interest received | | 6,427 | - |
| | Net cash flow used in investing activities | В | (8,04,807) | - |
| | Net increase (decrease) in cash and cash equivalents | 4+B | 1,70,102 | (1,50,993) |
| | | | 1,21,408 | 2,72,401 |
| | Cash and cash equivalents at the end of the year (refer Note 3) | | 2,91,511 | 1,21,408 |
| The | accompanying Notes 1-13 form an integral part of the Financial Statements. | | | |

For Ghanshyam Parekh & Co. Firm Registration No. 131167W Chartered Accountants

G R Parekh

Proprietor

Membership No. F-030530

T.R Gopi Kannan President - Finance

Vishal Adesara

General Manager Finance - CP Division

Atul April 08, 2025

Atul Brasil Quimicos Ltda

Statement of changes in equity for the year ended on March 31, 2025

A. Equity share capital

| | | Brazilian Real (R\$) |
|---------------------------------|-------|----------------------|
| Particulars | Notes | Amount |
| As at April 01, 2023 | | 7.06.899 |
| Changes in equity share capital | | - |
| As at March 31, 2024 | | 7.06.899 |
| Changes in equity share capital | | - |
| As at March 31, 2025 | 6 | 7,06,899 |

B. Other equity

| | | Brazilian Real (R\$) | |
|--|-------------------|----------------------|--|
| | Reserve & Surplus | Total | |
| Particulars | Retained | Other | |
| | earnings | Equity | |
| As at April 01, 2023 | 9,96,700 | 9,96,700 | |
| Loss for the year | (4,41,093) | (4,41,093) | |
| Total comprehensive income for the year | (4,41,093) | (4,41,093) | |
| As at March 31, 2024 | 5,55,607 | 5,55,607 | |
| Profit for the year | 2,67,753 | 2,67,753 | |
| Dividend on equity share | (8,11,234) | (8,11,234) | |
| Total comprehensive income for the year | 2,67,753 | 2,67,753 | |
| As at March 31, 2025 | 12,126 | 12,126 | |
| The accompanying Notes 1-13 form an integral part of the Financial Statements. | | | |

For Ghanshyam Parekh & Co.

Firm Registration No. 131167W

Chartered Accountants

G R Parekh

Proprietor

Membership No. F-030530

T.R Gopi Kannan President - Finance

Vishal Adesara

General Manager Finance - CP Division

April 08, 2025



Atul Brasil Quimicos Ltda

Notes to the Financial Statements

Background

Atul Brasil Qumicos Ltda (the 'Company') is a limited company incorporated and domiciled in Brazil. It is a subsidiary company of Atul Ltd (Holding company). The Company is engaged in providing marketing services to its Holding Comapny in South America.

Note 1 Material Accounting Policies

a) Basis of preparation:

The Special Purpose Financial Statements ('Financial Statements') have been prepared by the Company solely for the purpose of submission to Authorised Dealer Category-I bank or the Reserve Bank of India (RBI) or any other regulatory authority as required under applicable regulations in connection with Annual Performance Report (APR) filing and for inclusion in the Consolidated Financial Statements of the Parent Company.

The Financial Statements comply in all material respects with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the Act) read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and other relevant provisions of the Act, as amended.

All the assets and liabilities have been classified as current or non-current as per the normal operating cycle of the Company and other criteria set out in Schedule III to the Companies Act, 2013. Based on the nature of service and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

b) Revenue recognition:

a) Other operating revenue:

Commission income is accounted for in the year in which the right to receive the same is established.

c) Employee benefits:

- a) All employee benefits payable within twelve months of service such as salaries, wages, bonus, ex-gratia, medical benefits etc. are recognised in the year in which the employees render the related service.
- Short-term leave encashment:
 Short-term leave encashment is provided at undiscounted amount during the accounting period based on service rendered by employees.

d) Taxation:

Tax for Atul Brasil is levied at the time of receipt of Income. Such taxes paid on receipts are charged to P&L under the head tax on commission income in the financial year of receipt.

e) Cash and cash equivalents:

In the Cash Flow Statement, cash and cash equivalents include cash on hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

f) Statement of cash flows

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash generated from | (used) in operating, investing and financing activities of the Company are segregated.

g) Trade receivables

Trade receivables are recognised at the amount of transaction price (net of variable consideration) when the right to consideration becomes unconditional. These assets are held at amortised cost, using the effective interest rate (EIR) method where applicable, less provision for impairment based on expected credit loss. Trade receivables overdue more than 180 days are considered in which there is significant increase in credit risk.

h) Trade Payable

These amounts represent liabilities for goods and services provided to the Group prior to the end of financial year which are unpaid. Trade payable are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised intinally at their fair value and subsequently measured at amortised costs using the EIR method.

i) Earnings per share:

Earnings per share (EPS) is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted EPS, the net profit for the period attributable to equity shareholders and the weighted average number of equity shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Critical estimates and judgments:

The preparation of Financial Statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. This note provides an overview of the areas that involved a higher degree of judgment or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be different than those originally assessed. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation for each affected line item in the Financial Statements.

Estimates and judgments are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances.

20520

| Note 2 | | As | at | Brazili As c | n† |
|---|--|--|--|---|--|
| | Trade receivables | March 3 | | March 31 | |
|) | Considered good - unsecured | | | | |
| i) | Related parties | | 4,90,386 | | 82,170 |
| | Total receivables | | 4,90,386 | | 82,170 |
| | | | ······································ | | an Real (R\$ |
| lote 3 | Cash and cash equivalents | As March 3 | | As o March 31 | |
| a) | Balances with banks | | -, | march of | ., 2021 |
| i) | In current accounts | | 2,91,511 | | 1,21,40 |
| here a | re no repatriation restrictions with regard to cash and cash equ | ivalents. | 2,91,511 | | 1,21,400 |
| | | | | | an Real (R\$ |
| ote 4 | Other Financial assets | As March 3 | | As o March 31 | |
| i) | Accured commission | | - 1 | | 13,12,12 |
| | | | - | | 13,12,128 |
| | | | ······································ | | an Real (R\$ |
| ote 5 | Other current assets | As March 3 | | As o March 31 | |
| i) | Prepaid expenses | | 21,510 | March 31, 2024 17,91 | |
| | | | 21,510 | | 17,910 |
| | | | | Brazil | ian Real (R\$ |
| | | As March 3 | | As o March 31 | |
| lote 6 | Equity share capital | Number of | | Number of | |
| | | shares | (R\$) | shares | (R\$) |
| uthor quity s | i sed shares of R\$ 1 (Brazilian Real) each | 7.06.899 | 7.06,899 | 7.06,899 | 7.06.899 |
| | | | 706899 | | 706899 |
| ssued auity | shares of R\$ 1 (Brazilian Real) each | 7,06,899 | 7,06,899 | 7.06,899 | 7.06,899 |
| | | 7,00,033 | 706899 | 7,00,033 | 70689 |
| ubscr | ibed shares of R\$ 1 (Brazilian Real) each | 7,06,899 | 7.06.000 | 7.06.000 | 7.06.000 |
| .quity : | situres of N. F. I (Bruzillutt Neut) euch | 7,06,899 | 7,06,899 706899 | 7,06,899 | 7,06,899 70689 9 |
| 1) | Movement in equity share capital | | | | |
| ., | merement in equity share capital | | | | the same and the s |
| | | ······ | | Brazil | ian Real (R\$ |
| | Particulars | Number (| of shares | Brazil Equity sha i | |
| | Particulars As at April 01, 2023 | Number | of shares 7,06,899 | | re capital |
| | | Number | | | re capital 7,06,899 |
| | As at April 01, 2023 | Number (| 7,06,899 | | re capital 7,06,899 7,06,899 |
| | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. | shares having a par value of R\$ 1/ E | 7,06,899 7,06,899 7,06,899 | Equity sha | 7,06,89 7,06,89 7,06,89 |
| No | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity | shares having a par value of R\$ 1/ E | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity sha | 7,06,89 7,06,89 7,06,89 7,06,89 |
| 10 | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. | shares having a par value of R\$ 1/ E pany of holding company as below: Number | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity shan | 7,06,899 7,06,899 7,06,899 7,06,899 itled to one |
| | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary comp | shares having a par value of R\$ 1/ E pany of holding company as below: | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity shares is ent Equity shares Holding | 7,06,899 7,06,899 7,06,899 itled to one |
| 1 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary company of the shareholder | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity shares is ent Equity shares Holding 96 99.69 | 7,06,89 7,06,89 7,06,89 7,06,89 itled to one re capital Number of shares 7,04,71 |
| 1 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary comp | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity shares is enterest Equity shares Holding 99.69 | 7,06,899 7,06,899 7,06,899 itled to one re capital Number of shares 7,04,71 2,18 |
| 1 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary company of the shareholder | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity shares is ent Equity shares Holding 96 99.69 | 7,06,899 7,06,899 7,06,899 itled to one re capital Number of shares 7,04,71 2,18 |
| 1 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary company of the shareholder | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 | Equity shares is entered to the shares in the shares is entered to the shares in the shares is entered to the shares in the shares in the shares is entered to the shares in the shares | 7,06,89 7,06,89 7,06,89 7,06,89 itled to one re capital Number of shares 7,04,71 2,18 7,06,99 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary company of the shareholder | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 ach holder of equi | Equity shares is entered to the shares in the shares is entered to the shares in the shares is entered to the shares in the shares in the shares is entered to the shares in the shares | re capital 7,06,89 7,06,89 7,06,89 7itled to one re capital Number of shares 7,04,71 2,18 7,06,99 ian Real (R\$ |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary comp Name of the shareholder ul Ltd ul Bioscience Ltd Other equity Retained earnings | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 | Equity shares is entered by the shares in the shares is entered by the shares is entered by the | re capital 7,06,89 7,06,89 7,06,89 7,06,89 itled to one re capital Number of shares 7,04,71 2,18 7,06,99 ian Real (R\$att, 2024 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary comp Name of the shareholder Ul Ltd Ul Bioscience Ltd Other equity Retained earnings Balance as at the beginning of the year | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 at at 31, 2025 | Equity shares is entered by the shares in the shares is entered by the shares is entered by the | re capital 7,06,89 7,06,89 7,06,89 7itled to one re capital Number of shares 7,04,71 2,18 7,06,99 ian Real (R\$ at 1, 2024 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary comp Name of the shareholder ul Ltd ul Bioscience Ltd Other equity Retained earnings | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 | Equity shares is entered by the shares in the shares is entered by the shares is entered by the | re capital 7,06,89 7,06,89 7,06,89 7itled to one re capital Number of shares 7,04,71 2,18 7,06,99 ian Real (R\$ at 1, 2024 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary compounds of the shareholder Il Ltd Il Bioscience Ltd Other equity Retained earnings Balance as at the beginning of the year Add: Profit (loss) for the year | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 at 31, 2025 | Equity shares is entered by the shares in the shares is entered by the shares is entered by the | re capital 7,06,89 7,06,89 7,06,89 itled to one re capital Number of shares 7,04,71 2,18 7,06,99 at 1, 2024 9,96,70 -4,41,09 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary compounds of the shareholder Ul Ltd Ul Bioscience Ltd Other equity Retained earnings Balance as at the beginning of the year Add: Profit (loss) for the year Dividend on equity share | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 | 7,06,899 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 at 31, 2025 5,55,607 2,67,753 -8,11,234 | Equity shares is entered by the shares in the shares is entered by the shares is entered by the | re capital 7,06,89 7,06,89 7,06,89 itled to one re capital Number of shares 7,04,71 2,18 7,06,99 ian Real (R\$ at 1, 2024 9,96,70 -4,41,09 - 5,55,607 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary compounds of the shareholder Ul Ltd Ul Bioscience Ltd Other equity Retained earnings Balance as at the beginning of the year Add: Profit (loss) for the year Dividend on equity share | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 As March 3 | 7,06,899 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 at 31, 2025 5,55,607 2,67,753 -8,11,234 12,126 | Equity shares is ent Equity shares Holding 96 99.69 0.31 100 Brazil As March 3 | 7,06,899 7,06,899 7,06,899 itled to one re capital Number of shares 7,04,71 2,186 7,06,999 ian Real (R\$ at 1, 2024 9,96,700 -4,41,099 5,55,607 |
| 1 At 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary comp Name of the shareholder Ul Ltd Ul Bioscience Ltd Other equity Retained earnings Balance as at the beginning of the year Add: Profit (loss) for the year Dividend on equity share Balance as at the end of the year | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 As March 3 | 7,06,899 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 at 31, 2025 5,55,607 2,67,753 -8,11,234 12,126 | Equity shares is ent Equity sha Holding 96 99.69 0.31 100 Brazil As March 3 | re capital 7,06,899 7,06,899 7,06,899 itled to one re capital Number of shares 7,04,71 2,188 7,06,999 ian Real (R\$ at 1, 2024 9,96,700 -4,41,099 5,55,607 |
| 2 At | As at April 01, 2023 As at March 31, 2024 As at March 31, 2025 The Company has one classes of shares referred to as equity vote per share. The shares are held by holding company and subsidiary compounds of the shareholder Ul Ltd Ul Bioscience Ltd Other equity Retained earnings Balance as at the beginning of the year Add: Profit (loss) for the year Dividend on equity share Balance as at the end of the year | shares having a par value of R\$ 1/ E pany of holding company as below: Number Holding % 99.69 0.31 100 As March 3 | 7,06,899 7,06,899 7,06,899 7,06,899 ach holder of equi of shares Number of shares 7,04,711 2,188 7,06,899 at 31, 2025 5,55,607 2,67,753 -8,11,234 12,126 | Equity shares is ent Equity shares Holding 96 99.69 0.31 100 Brazil As March 3 | 7,06,899 7,06,899 7,06,899 7,06,899 7,06,899 iitled to one re capital Number of shares 7,04,71 2,181 7,06,999 iian Real (R\$ at 1, 2024 |

| | Brazi | lian Real (R\$) |
|---|---------------------------------------|-----------------|
| Note 9 Revenue from operations | 2024-25 | 2023-24 |
| Other operating revenue | | |
| i) Commission income | 5,06,065 | 5,28,733 |
| | 5,06,065 | 5,28,733 |
| | Brazi | lian Real (R\$) |
| Note 10 Other income | 2024-25 | 2023-24 |
| Interest from banks | 6,427 | - |
| Expense recovered | 1,83,470 | - |
| Net exchange rate difference gain (loss) | 1,59,057 | (50,122) |
| Provision no longer required | 2,00,272 | - |
| | 5,49,226 | (50,122) |
| Note 11 Employee benefit expenses Salaries, wages and bonus | Brazi 2024-25 | lian Real (R\$) |
| Salaries, wages and bonus | 5,12,694 | |
| | 5,12,694 5,12,694 | 4,93,000 |
| | Brazi | lian Real (R\$) |
| Note 12 Other expenses | 2024-25 | 2023-24 |
| Bank charges | 10,808 | 5,631 |
| Legal and professional charges | 75,962 | 1,97,694 |
| Sundry debit balance written off | _ | 1,98,765 |
| Telephone expenses | 3,425 | 3,021 |
| Internet expenses | 1,500 | 1,889 |
| Transplication and accommon | · · · · · · · · · · · · · · · · · · · | |
| Travelling and conveyance | 1,43,395 | 14,412 |
| Books and periodicals Miscellaneous expenses | 1,43,395 24,000 | 14,412 |



2,74,844

4,26,704

| NOTE | 13.1 Polated party disclosures | |
|------|--|--|
| A) R | - 13.1 Related party disclosures elated party information: | |
| Nam | o of rolated party and nature of rolationship | |
| No | Name of the related party | Description of relationship |
| 01. | Atul Ltd | Lolding company |
| 02. | | Holding company |
| 03. | Aaranyak Urmi Ltd Aasthan Dates Ltd | |
| | Amal Ltd | |
| | Amal Speciality Ltd | |
| | Atul Adhesives Private Ltd | |
| | | |
| 08. | Atul Arun ada Ita | |
| | Atul Ayurveda Ltd Atul Bioscience Ltd | |
| | | |
| | Atul Ching Ltd | |
| | Atul Class Faces Ltd | |
| | Atul Consumer Products Ltd | |
| | Atul Consumer Products Ltd Atul Crop Care Ltd | |
| | Atul Deutschland GmbH | |
| | Atul Entertainment Ltd | |
| | Atul Europe Ltd | |
| | Atul Fin Resources Ltd | |
| | Atul Fin Resources Ltd Atul Finserv Ltd | |
| | Atul Hospitality Ltd | |
| | Atul Healthcare Ltd | |
| | Atul Infotech Pvt Ltd | |
| 23. | Atul Ireland Ltd | Subsidiary companies of holding company |
| 24. | Atul Lifescince Ltd | |
| 25. | Atul Middle East FZ-LLC | |
| | Atul Natural Dyes Ltd | |
| | Atul Natural Foods Ltd | |
| 28. | Atul Nivesh Ltd | |
| | Atul Paints Ltd | |
| | Atul Polymers Products Ltd | |
| | Atul Products Ltd | |
| | Atul Rajasthan Date Palms Ltd | |
| 33. | Atul Renewable Energy Ltd | |
| 34. | Atul (Retail) Brands Ltd | |
| 35. | Atul Seeds Ltd | |
| | Atul USA Inc | |
| | Biyaban Agri Ltd | |
| | DPD Ltd | |
| 39. | Jayati Infrastructure Ltd | |
| 40. | Osia Dairy Ltd | |
| 41. | Osia Infrastructure Ltd | |
| 42. | Raja Dates Ltd | |
| 43. | Sehat Foods Ltd | |
| 44. | Valsad Institute of Medical Sciences Ltd | Associate company of holding company |
| 45. | Rudolf Atul Chemicals Ltd | Joint venture company of holding company |
| 46. | Anaven LLP | Joint operation of subsidiary company of holding company |
| | | |



Brazilian Real (R\$) (B) Transactions with holding company **Particulars** 2024-25 2023-24 Sales and income Commission income 01. Atul Ltd 5,06,065 5,28,733 02. Dividend paid on equity 8,11,234 Atul Ltd 8,08,723

(C) outstanding balances as at year end

Atul Bioscience Ltd

| | Particulars | As at March 31,2025 | As at March 31,2024 |
|-----|--------------------|------------------------|------------------------|
| 01. | Receivables | 3,06,917 | 1285817 |
| | Atul Ltd | 3,06,917 | 12,85,817 |
| 02. | Payable | - | 2,00,272 |
| | Atul Crop Care Ltd | - | 2,00,272 |

Note 13.2 Authorisation for issue of the Financial Statements

The Financial Statements were authorised for issue by the Management on April 08, 2025.

For Ghanshyam Parekh & Co. Firm Registration No. 131167W

Chartered Agrountants

G R Parekh

Proprietor

Membership No. F-030530

T.R Gopi Kannan

President - Finance

Vishal Adesara

General Manager Finance - CP Division

2,511

Atul

April 08, 2025